Page last updated: 2024-08-18

pyrazolanthrone and Cardiac Diseases

pyrazolanthrone has been researched along with Cardiac Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Drosatos, K; Drosatos-Tampakaki, Z; Goldberg, IJ; Homma, S; Khan, R; Schulze, PC; Zannis, VI	1

Other Studies

1 other study(ies) available for pyrazolanthrone and Cardiac Diseases

Article	Year
Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. The Journal of biological chemistry, 2011, Oct-21, Volume: 286, Issue:42 Topics: Animals; Anthracenes; Cell Line; Fatty Acids; Gene Expression Regulation; Heart Diseases; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Mice; Mice, Knockout; Muscle Proteins; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; PPAR alpha	2011

Article

Year

Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction.

The Journal of biological chemistry, 2011, Oct-21, Volume: 286, Issue:42

Topics: Animals; Anthracenes; Cell Line; Fatty Acids; Gene Expression Regulation; Heart Diseases; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Mice; Mice, Knockout; Muscle Proteins; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; PPAR alpha

2011